NCT04012411 · RECRUITING
Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease
This study looks at Huntington's disease, not Alzheimer's. Researchers are measuring markers of the BDNF pathway, a system that helps brain cells survive and connect, in spinal fluid and blood. Participants also have a brain MRI and thinking tests. Nothing is being tested as a drug. It is an observational biomarker study with no phase.
Eligibility criteria
Inclusion Criteria: * General inclusion criteria: * age ≥ 18 years-old * national health insurance cover * Patients inclusion criteria: * genetically confirmed Huntington's disease diagnosis (≥ 35 CAG repeat in HTT gene exon 1) * written informed consent * only for patients "with lumbar puncture (LP)": patient agreement for LP * Control inclusion criteria: * anterior LP for medical reason with consent for biobank "Neuro" with following samples present in this biobank : 2 mL blood + 0.5 mL plasma + 0.5 mL cerebrospinal fluid * information and non-opposition for the finality of this biobank * paired by age with a patient (+/- 5 years difference) Exclusion Criteria: * General exclusion criteria: * protected by law * Patients exclusion criteria: * Huntington's disease stage too Evolved that may interfere with cognitive evaluations or MRI * contraindications to brain MRI * only for patients "with LP": contraindications to LP * incapacity to give informed consent * Control exclusion criteria: * neurodegenerative of inflammatory central nervous system pathology
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-02-12